
30-day deadline for making an application to participate; in the EU, the FMD program is progressing
30-day deadline for making an application to participate; in the EU, the FMD program is progressing
Diligent Health Solutions banks on experienced management
Will restricting use of rebates in federal programs carry over to commercial insurance?
A marketing challenge: how to make more adults aware of anti-bacterial booster shots
Expansions in the capability of supply chain participants to manage temperature-controlled pharmaceuticals
Senate and House committees begin the legislative process for addressing drug pricing
Annual analysis predicts 3-6% CAGR through 2023, a lower rate than 2014-2018
Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost
Broader capabilities for refrigerated or cryogenic transport of cellular materials
Signs up Bayer Health for pulmonary hypertension and MS
Nov. 27, 2018, was to be a red-letter day in the 10-year program to implement an end-to-end pharma traceability system. Did industry meet the deadline?
Programs provide copay and other financial assistance
Field trial results to be unveiled at upcoming meeting
Partnership with Dacos A/S; FDA will look closer at cellular and genetic therapies
Spending on drug promotion rose—but not at the rate of pharma sales growth
Sandoz and Pear Therapeutics tackle opioid use disorder
Strengthening a leading player in track-and-trace packaging technology
A deeper commitment to oncology and immunology
List includes 25 orphan drugs; there were also seven additional biosimilars
Flu activity is “elevated” nationally; Walgreens sees a hotspot in Nebraska
Nearly a million US citizens live with HIV, a virus that still lacks a curative therapy
Cellular and genetic therapies (CGTs) developers are struggling to build capacity
Oncology represents half of the dollar volume of HDA-member sales
Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals
Action consolidates leading courier companies with larger freight forwarders
Sales volume handled by primary wholesaler/distributors seems to be declining
The carbon footprint of shipping alternatives is also becoming a competitive issue
$360-million settlement involved assistance funneled through a charity
HFAP builds out from its hospital-accreditation business